Aptevo Therapeutics : September 29, 2021 Investor Presentation

Published: 2021-09-29 16:22:18 ET APVO

29 September 2021

Aptevo Therapeutics

A Leading Bispecific Antibody Company

NASDAQ: APVO

Forward-Looking Statements

This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our financial guidance, product portfolio, product sales, capabilities, potential partnerships and collaborations, the ability of therapeutic candidates to function as designed in preclinical and clinical development, the continued advancement of product candidates in preclinical development and clinical trials, our goals and milestones, our expectations regarding the size of the patient populations for our therapeutic product candidates if approved for commercial use, our expectations regarding the safety and effectiveness of our ADAPTIR and ADAPTIR-FLEX platform technologies and our therapeutic product candidates, our ability to obtain regulatory approval for our therapeutic product candidates, our choice of funding sources and our ability to obtain non-dilutive funding, our expectations of future warrant exercises and the resulting impact to our cash position as a result thereof, the monetization of RUXIENCE and IXINITY payment streams, and any other statements containing the words "believes", "expects", "anticipates", "intends", "plans", "forecasts", "estimates" and similar expressions in conjunction with, among other things, discussions of financial performance or financial condition, growth strategy, product sales, manufacturing capabilities, product development, regulatory approvals or expenditures are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this presentation, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward- looking statements, including possible negative effects on Aptevo's business operations, assets or financial results as a result of the separation; a deterioration in the business or prospects of Aptevo; adverse developments in Aptevo's customer-base or markets; our ability to enter into and maintain selective collaboration and partnership arrangements; the timing of and our ability to achieve milestones in collaboration and partnership contracts; our ability and the ability of our contractors and suppliers to maintain compliance with cGMP and other regulatory obligations; the results of regulatory inspections; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs; the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic product candidates; and our commercialization, marketing and manufacturing capabilities and strategy and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in our filings with the Securities and Exchange Commission (the SEC), including Aptevo's most recent Annual Report on Form 10-K, as filed on March 25, 2020, and its subsequent reports on Form 10-Q and current reports on Form 8-K.

The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.

Aptevo™, ADAPTIR™ and any and all Aptevo Therapeutics Inc. brand, product, service, and feature names, logos, and slogans are trademarks

or registered trademarks of Aptevo Therapeutics Inc. or its subsidiaries in the United States or other countries. All rightsreserved.

Aptevo at-a-Glance

(1)

Data as of May 26, 2021

(2)

Active IND, initiation of enrollment pending

Experienced Leadership

Senior Management

Board of Directors

Marvin White - President & CEO

Marvin White

Emergent Director; Former CFO, St. Vincent's Health;

Former Executive Director & CFO, Lilly USA

Jeff Lamothe - SVP, CFO

Fuad El-Hibri

Former Emergent VP, Finance; Former CFO, Cangene

Founder, Executive Chairman, Emergent BioSolutions

Corporation

Daniel Abdun-Nabi

Jane Gross, Ph.D. - SVP, CSO*

Former President & CEO, COO, Emergent BioSolutions,

Former Emergent VP, Research/Non-Clinical Development;

Former General Counsel, IGEN International, Inc.

Former VP Immunology Research ZymoGenetics Inc.

Grady Grant, III

SoYoung Kwon - SVP, GC, Corporate Affairs &

Former Vice President of Sales, Tissue Tech Limited;

Former Reckitt Benckiser Group; Former Eli Lilly & Co.

Former SVP, GC and Corporate Secretary, AGC Biologics

Zsolt Harsanyi, Ph.D.

Daphne Taylor - VP, Finance

N-Gene Research Labs; Exponential Biotherapies;

Porton Int'l

Former CFO, BioLife Solutions; Former CAO, Cardiac Science

Barbara Lopez Kunz

Corporation

DIA; Battelle; Thermo Fisher Scientific; ICI/Uniqema

John Niederhuber, M.D.

Inova Translational Medicine Institute; National Cancer

Institute; Johns Hopkins University

Extensive R&D, Manufacturing, Commercial

and Financial Expertise and Experience

*Dr. Gross is a consultant to thecompany.

Robust Pipeline: Potential for Multiple Shots on

Goal in Hematologic Malignancies and Solid Tumors

Product/

Technology

Potential

Pre-

Clinical Development Stage

Marketed

Milestones/Highlights

Candidate

Indications

Clinical

Phase

Target

III

APVO436

Redirected T cell

Phase 1 dose escalation

AML/MDS

reported positive results;

Cytotoxicity

CD3/CD123

Part 2 dose expansion

(RTCC)

activated

APVO436

Redirected T cell

AML/MDS

Selected Participant:

Leukemia/Lymphoma

CD3/CD123

Cytotoxicity

Society "Beat AML" Trial

ALG.APV-527*

T cell Co-

Solid

CTA filing underway,

FIH anticipated in 2021,

4-1BB/5T4

Stimulation

Tumors

Collaboration with

Alligator Bioscience

APVO603

Dual T cell

Solid

Unique asset for use in

solid tumors, advancing

4-1BB/OX40

Co-stimulation

Tumors

lead candidate

APVO442

Redirected T cell

Prostate

Low affinity CD3,

Cancer

PSMA/CD3

Cytotoxicity

advancing lead candidate

(CRPC)

Disclaimer

Aptevo Therapeutics Inc. published this content on 29 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 September 2021 20:21:09 UTC.